26.49
+0.28(+1.07%)
Currency In USD
| Previous Close | 26.21 |
| Open | 26.04 |
| Day High | 26.9 |
| Day Low | 26.02 |
| 52-Week High | 44.32 |
| 52-Week Low | 21.62 |
| Volume | 3.61M |
| Average Volume | 2.03M |
| Market Cap | 5.01B |
| PE | -10.95 |
| EPS | -2.42 |
| Moving Average 50 Days | 25.73 |
| Moving Average 200 Days | 26.63 |
| Change | 0.28 |
If you invested $1000 in BridgeBio Pharma, Inc. (BBIO) since IPO date, it would be worth $961.52 as of December 21, 2024 at a share price of $26.49. Whereas If you bought $1000 worth of BridgeBio Pharma, Inc. (BBIO) shares 3 years ago, it would be worth $625.35 as of December 21, 2024 at a share price of $26.49.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
GlobeNewswire Inc.
Dec 13, 2024 12:18 PM GMT
The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of acoramidis in the EU based on positive results from the Phase 3 ATTRibute-CM study; final approval decision, typically consistent with the CHMP recommendation,
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
GlobeNewswire Inc.
Nov 23, 2024 12:11 AM GMT
- Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby has been shown to preserve the native function of TTR as a transport protein of thyroxine and vitamin A and to demonstrate benefit on
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
GlobeNewswire Inc.
Nov 18, 2024 4:15 PM GMT
- Acoramidis demonstrated the earliest known time to separation in cardiovascular outcomes in the ATTRibute-CM study (3 months), with statistically significant risk reduction of 36% on All-Cause Mortality (ACM) alone at Month 36 within the Open Label